Company Overview
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Why Investors Should Care
Revenue has grown at a 24.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.05.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -58.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 24.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 24.09% |
| 1 Year: | -58.40% |
Stock Price Performance
| 1 Year: | +18.06% |
| 6 Months: | -37.54% |
| 3 Months: | +8.28% |
| 1 Month: | +0.55% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.48 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 24.1% over 5 years.
CONS
- Trading 56.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GANX Gain Therapeutics, Inc. PHARMA | 1.83 | -3.66 | $79.87M | 0.00% | -96.12% | - | 24.09% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 81.62K | 15.97K | 37.54K | 95.10K | - | 55.18K | - | - | - | - | - | - | - | - | - |
| Operating Income | -512.26K | -532.47K | -819.09K | -2.47M | -3.51M | -4.64M | -3.29M | -5.18M | -4.75M | -5.23M | -7.73M | -4.89M | -4.38M | -8.18M | -4.46M | -4.37M | -5.09M | -4.79M | -5.35M |
| Net Income | -584.27K | -543.36K | -794.37K | -2.45M | -3.56M | -4.66M | -3.27M | -5.09M | -4.56M | -5.14M | -7.69M | -4.72M | -4.01M | -8.14M | -4.49M | -4.53M | -5.81M | -5.28M | -5.61M |
| Diluted EPS | - | -0.27 | -0.25 | -0.50 | -0.30 | -0.39 | -0.28 | -0.43 | -0.38 | -0.43 | -0.62 | -0.37 | -0.22 | -0.42 | -0.17 | -0.16 | -0.19 | -0.15 | -0.13 |
| R&D Expense | 417.26K | 438.87K | 427.46K | 1.42M | 1.79M | 2.48M | 1.56M | 2.58M | 1.96M | 2.79M | 3.99M | 2.37M | 2.51M | 4.44M | 2.62M | 2.26M | 2.76M | 2.85M | 2.76M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 28.88K | 133.93K | 132.64K | 55.18K | - | - |
| Operating Income | -3.48M | -13.83M | -17.78M | -22.25M | -20.35M | -18.71M |
| Net Income | -3.58M | -13.89M | -17.59M | -22.27M | -20.41M | -20.16M |
| Diluted EPS | -1.33 | -1.37 | -1.48 | -1.71 | -0.89 | -0.61 |
| R&D Expense | 2.26M | 7.16M | 8.38M | 11.52M | 10.79M | 10.21M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 9.60M | 38.99M | 24.10M | 18.61M | 12.12M | 22.82M |
| Total Equity | -449.86K | 6.20M | 34.82M | 18.88M | 12.58M | 7.34M | 18.56M |
| Cash & Equivalents | - | 7.49M | 36.88M | 7.31M | 11.79M | 10.39M | 20.84M |
| Long Term Debt | - | 715.66K | 590.47K | 495.26K | 449.05K | 328.33K | 300.08K |
| Total Liabilities | - | 3.40M | 4.17M | 5.22M | 6.03M | 4.78M | 4.25M |
| Current Liabilities | - | 2.11M | 2.55M | 4.13M | 4.95M | 3.91M | 3.35M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.24M | -12.37M | -14.69M | -18.87M | -18.87M | -18.47M |
| Investing Cash Flow | -20.83K | -94.21K | -14.77M | 10.22M | 4.98M | - |
| Financing Cash Flow | 10.49M | 41.77M | -78.77K | 12.64M | 13.01M | 28.45M |
| Capital Expenditure | -20.83K | -94.21K | - | - | - | - |
| Free Cash Flow | -3.26M | -12.46M | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -12,047.5% | -10,323.6% | -13,402.5% | -40,328.3% | - | - |
| Net Margin % | -12,387.7% | -10,371.7% | -13,262.0% | -40,354.3% | - | - |
| ROE % | -57.7% | -39.9% | -93.2% | -177.0% | -278.1% | -108.6% |
| ROCE % | -46.5% | -38.0% | -89.0% | -162.9% | -247.8% | -96.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Marshall Wace LLP | 4.41% | 1.92M | $3.39M |
| 2 | Potomac Capital Management, Inc. | 2.17% | 946.40K | $1.67M |
| 3 | GSA Capital Partners LLP | 1.45% | 632.13K | $1.11M |
| 4 | Jones Financial Companies, L.L.L.P. | 1.39% | 608.59K | $1.07M |
| 5 | Cambridge Investment Research Advisors Inc. | 1.30% | 568.64K | $1.00M |
| 6 | DME Capital Management, LP | 1.30% | 566.13K | $996.39K |
| 7 | Vanguard Capital Management LLC | 1.10% | 480.27K | $845.27K |
| 8 | Geode Capital Management, LLC | 1.04% | 453.50K | $798.16K |
| 9 | Blackrock Inc. | 0.63% | 274.96K | $483.92K |
| 10 | Vanguard Fiduciary Trust Co | 0.53% | 231.53K | $407.50K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GANX
Why Is GANX Stock Rallying 22% After Hours? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPbzVDdTltMGJCVVAxTDFIa2RDVUFmVnRjYlhqYUdsZ21lZ2g2MFVpbWVtUVFzUVlSQTllcVBwdkY4R1UtODY4ZExza0tMbE02Uk04MFR3N2RPdWN6T2FTSG5rMjgxUXptU0JEUDQ4bnpBUE1Cc21kOXMtOUdwN1Z0R0xIdzVTMHBxWm5IM0…
Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNMFFpOWNoOEhDSXBMaWpoLXBmQkVkS1pZZ0JRSF9Ibk8xRGNpeVlzc2h3MkRiVnhwa3pPOXg3d2UwNE9FbVpGblZRVnAxMkttN3FmWVU4VnpROXlWSEpKeWw5aVVqQ3lyNmtpaUtwZDNROGdwWDY3WFNDOWFmQVQ5emF2VUZ4aFlaYngzVE…
FDA clears Gain Therapeutics drug GT-02287 for Phase 2 Parkinson’s trial - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQZFVEU1BYbmR2cWZEZExaaTVzc1FTdnl2VndNVnB0UVNYczZHOVdTVF92bDNFT1pvN2RBZDl0LVh2OFhSckJoaDJDWjdvVm9yZTBZVmQ3NUxNNElrM050MmxZTUMyeTJrQVUxNk5jenRVbW0xcGtUcVFzMHRZTm9RVEd1Q1B0Q1QtMU5tSm…
GANX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBSQjNsUmxuQ1NEZ0NQOHV0b1EyVXJJazdDOGJGdUtnUzUtMnRJS1paZkFOX2g1NzdVaDBmOHgyTEhCVEZpYWtHZ01SWUV4WktkZ3E4Tkoxb183cFN2Q0RNc21VRVV1Ums2cTZBRUNsaVAwUDFETHJHemJR?oc=5" target="_blank">GAN…
GANX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE96ek1mZ2hSVFFuUzBqaUFWWVFPay1rUVhUZjlYVnBMbWlpSU0wNkZNZGM5SWRvcm5GTm1GbXZha09MSEEzc1E?oc=5" target="_blank">GANX</a> <font color="#6f6f6f">Finviz</font>…
H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval - Investing.com
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPemdjWmZZOHhUMG9fZ1daU1pkcHA1QllvWFBSNWJtU2htRV9xYm9NRnhHa2x6Ull1RnhoS1NHUC1vNTh1YXRtQkJpNVpIMFo3U0IxeHJ0dmZlekpLanFJb3dydXlEbEFGM3hQb1FFQzVkd3pqU0lETGV6LU1QLVpwcnFCWkk0ZXdsZ3lXdX…
GANX — Frequently Asked Questions
What is the current share price of Gain Therapeutics, Inc. (GANX)?
As of 2026-09-19 21:16 PDT, Gain Therapeutics, Inc. (GANX) trades at $1.83 on NasdaqGM. Its 52-week range is $1.54 to $4.18.
What is the market capitalisation of GANX?
Gain Therapeutics, Inc. (GANX) has a market capitalisation of $79.87M on NasdaqGM.
What is the P/E ratio of GANX?
GANX trades at a trailing price-to-earnings (P/E) ratio of -3.66. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 6.74.
Is GANX a good stock to buy?
This page provides a data-driven analysis of Gain Therapeutics, Inc. (GANX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.